Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024 [Yahoo! Finance]
Cabaletta Bio, Inc. (CABA)
Company Research
Source: Yahoo! Finance
Title: Safety and Efficacy of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-Myositis™ and RESET-SLE™ Clinical Trials Abstract ID: Date and Time: Sunday, November 17, 2024, 3:30 p.m. – 3:45 p.m. ET Presenter: David J. Chang, M.D., M.P.H, FACR, Chief Medical Officer, Cabaletta Bio Poster Presentation: Title: Correlative Studies of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-Myositis™ and RESET-SLE™ Clinical Trials Abstract ID: Date and Time: Saturday, November 16, 2024, 10:30 a.m. – 12:30 p.m. ET Presenter: Daniel Nunez, Ph.D., Director, Computational Biology at Cabaletta Bio Additional information, including the accepted abstracts, can be accessed on the ACR Convergence 2024 website . Presentation materials will be
Show less
Read more
Impact Snapshot
Event Time:
CABA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CABA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CABA alerts
High impacting Cabaletta Bio, Inc. news events
Weekly update
A roundup of the hottest topics
CABA
News
- Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024GlobeNewswire
- Cabaletta Bio, Inc. (NASDAQ: CABA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.MarketBeat
- Cabaletta Bio to Participate in Upcoming Investor Conferences in SeptemberGlobeNewswire
- Several Headwinds Dragged Cabaletta Bio (CABA) in Q2 [Yahoo! Finance]Yahoo! Finance
- Cabaletta Bio, Inc. (NASDAQ: CABA) had its price target lowered by analysts at Wells Fargo & Company from $35.00 to $20.00. They now have an "overweight" rating on the stock.MarketBeat
CABA
Earnings
- 8/8/24 - Miss
CABA
Sec Filings
- 8/22/24 - Form SC
- 8/8/24 - Form 10-Q
- 8/8/24 - Form 8-K
- CABA's page on the SEC website